Lapatinib

證據等級: L5

預測適應症: 1 個

Lapatinib: Drug Repurposing Evaluation Report

One-Sentence Summary

Lapatinib is a dual tyrosine kinase inhibitor targeting HER2 (ErbB2) and EGFR (ErbB1), originally developed for HER2-positive advanced breast cancer. This Evidence Pack is critically incomplete: the predicted_indications field is empty, meaning no TxGNN repurposing predictions are available for evaluation at this time. Without a predicted new indication, a full repurposing analysis cannot be generated — a Hold decision applies until the Evidence Pack is completed.

Quick Overview

Item	Content
Original Indication	HER2-positive advanced or metastatic breast cancer (from domain knowledge; not present in Evidence Pack)
Predicted New Indication	Not available — `predicted_indications` is empty
TxGNN Prediction Score	Not available
Evidence Level	Cannot be determined
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack (original_moa: [Data Gap]). Based on publicly known pharmacology, Lapatinib (DrugBank ID: DB01259) is a small-molecule, reversible dual inhibitor of the intracellular tyrosine kinase domains of HER2/ErbB2 and EGFR/ErbB1. By blocking downstream RAS/MAPK and PI3K/AKT signalling pathways, it inhibits tumour cell proliferation and survival in HER2-overexpressing cancers.

Because no TxGNN prediction exists in this Evidence Pack, it is not possible to assess mechanistic plausibility for any specific new indication. Once a target indication is provided by the prediction pipeline, the mechanistic link between HER2/EGFR signalling and that disease can be formally evaluated.

This section will be completed once predicted_indications is populated.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Reason: predicted_indications is empty. Clinical trial evidence is indication-specific and cannot be retrieved without a target disease.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Reason: predicted_indications is empty. Literature evidence is indication-specific and cannot be retrieved without a target disease.

Finland Market Information

Lapatinib has 0 authorizations in the regulatory database queried. The drug is currently not marketed.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No authorizations on record

Cytotoxicity

Lapatinib is an antineoplastic targeted therapy (HER2/EGFR dual tyrosine kinase inhibitor). The following applies:

Item	Content
Cytotoxicity Classification	Targeted therapy — HER2/EGFR dual tyrosine kinase inhibitor
Myelosuppression Risk	Low to moderate (less myelosuppressive than conventional cytotoxics; neutropenia reported but less frequent)
Emetogenicity Classification	Low
Monitoring Items	Liver function tests (LFTs), cardiac function (LVEF), CBC, electrolytes (QTc monitoring required)
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key_warnings, contraindications, DDI) are marked as data gaps in the current Evidence Pack. The TFDA package insert query returned a result (query log ID 4, status: success), but the parsed content was not loaded into this Evidence Pack version. Remediation: parse the TFDA package insert PDF.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is missing the two most critical components for repurposing analysis — predicted_indications (TxGNN output) and original_moa — making it impossible to assess either the candidate indication or the mechanistic plausibility of the prediction.

To proceed, the following is needed:

[Blocking] Run TxGNN prediction pipeline for DB01259 and populate predicted_indications with at least one candidate disease, including txgnn.score, evidence.clinical_trials, and evidence.literature
[High] Retrieve Lapatinib MOA from DrugBank API (DrugBank query returned success with 1 result in query log ID 3 — this data should already be parseable)
[High] Parse TFDA package insert PDF (query log ID 4 returned success) to extract key_warnings and contraindications and resolve data gaps DG001/DG002
[Medium] Re-run DDI query with a broader search scope (current result: not_found; consider synonym or brand name search for Lapatinib/Tykerb)
Once predicted_indications is populated, regenerate this report using Evidence Pack v5+
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.